Recently, inhibitors disrupting the menin-MLL interaction have demonstrated promising therapeutic potential in preclinical studies and clinical trials for treating acute leukemia with MLL-AF fusions or NPM1 mutations [25]. Here, KMT2A is linked to acute leukemia.